In people with T2D, in a phase II study (281 participants) with a placebo, GLP-1 RA dulaglutide, and retatrutide, the triple receptor agonist peptide showed clinically meaningful improvements in glycemic control and body weight reduction dose-dependently at 36 weeks by 3.2%, 10.4%, 16.8%, and 16.9% (with doses of 0.5, 4, 8, and 12 mg once a week, respectively) compared to 3.0% with the placebo and 2.0% with a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists [180]. Here, GLP1R is linked to type 2 diabetes mellitus.